Jardiance Tablet, Film Coated
Product Images NDC 55154-0411

18 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 55154-0411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Jardiance 01)

Chemical Structure (Jardiance 01)
Chemical structure of Empagliflozin, the active ingredient in Jardiance. The diagram shows the molecular arrangement including several hydroxyl groups, aromatic rings, a chlorine atom, and an ether linkage consistent with the known structure of Empagliflozin.*
FDA Label Image

Figure 1 (Jardiance 02)

Figure 1 (Jardiance 02)
A chart showing the geometric mean ratio with 90% confidence intervals for the change in AUC and Cmax relative to empagliflozin alone. The chart compares multiple drugs including antidiabetic drugs such as Metformin, Glimepiride, Pioglitazone, Sitagliptin, Linagliptin, and others like Simvastatin, Warfarin, Verapamil, Ramipril, Gemfibrozil, Hydrochlorothiazide, Torsemide, Rifampicin, and Probenecid on the left with corresponding values plotted to the right.*
FDA Label Image

Figure 2 (Jardiance 03)

Figure 2 (Jardiance 03)
A forest plot chart showing geometric mean ratios with 90% confidence intervals for various drugs including antidiabetic drugs, oral contraceptives, and others. Drug names, doses, and administration frequencies are listed on the left, with corresponding AUC and Cmax values plotted to the right to indicate relative exposure and peak concentration comparisons.*
FDA Label Image

Figure 3 (Jardiance 04)

Figure 3 (Jardiance 04)
A line graph depicting the mean change from baseline in HbA1c percentage over 24 weeks for three groups: placebo, Empagliflozin 10 mg, and Empagliflozin 25 mg. The x-axis represents time in weeks, and the y-axis shows HbA1c percentage change. Empagliflozin groups show greater reduction compared to placebo, with error bars indicating variability.*
FDA Label Image

Figure 4 (Jardiance 05)

Figure 4 (Jardiance 05)
A line graph comparing mean change from baseline in HbA1c (%) over 52 weeks for two treatments: Glimepiride + Metformin and Empagliflozin 25 mg + Metformin. The x-axis represents time in weeks, and the y-axis shows percentage change in HbA1c from baseline. Data points highlight trends with both treatments reducing HbA1c, showing differences in effectiveness over time.*
FDA Label Image

Figure 5 (Jardiance 06)

Figure 5 (Jardiance 06)
A line graph comparing the percentage of patients with events over 48 months between placebo and empagliflozin treatment groups. The y-axis shows patients with events (%) and the x-axis represents time in months. The placebo group has a higher event rate compared to the empagliflozin group throughout the study period.*
FDA Label Image

Figure 6 (Jardiance 07)

Figure 6 (Jardiance 07)
A line graph comparing the percentage of patients with events over 48 months between placebo and all empagliflozin groups. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event. A table below the graph lists the number of subjects at risk at various time points for each group.*
FDA Label Image

Figure 7 (Jardiance 08a)

Figure 7 (Jardiance 08a)
A line chart comparing the estimated cumulative incidence function percentages over time between placebo and Empagliflozin 10 mg groups in a clinical study. The x-axis shows days since randomization, and the y-axis shows cumulative incidence percentage. The graph includes hazard ratio, confidence interval, and p-value statistics comparing Empagliflozin 10 mg to placebo.*
FDA Label Image

Figure 8 (Jardiance 08b)

Figure 8 (Jardiance 08b)
A line graph comparing the mean number of events over days since randomization for placebo and Empagliflozin 10 mg groups. The graph shows two curves, one solid for placebo and one dotted for Empagliflozin 10 mg, illustrating their respective event rates over time up to 810 days. The hazard ratio and p-value for Empagliflozin 10 mg versus placebo are also displayed.*
FDA Label Image

Figure 9 (Jardiance 08c)

Figure 9 (Jardiance 08c)
A forest plot illustrating hazard ratios comparing Empagliflozin 10 mg versus placebo across various patient subgroups, including diabetes status, age, sex, race, BMI, eGFR levels, NYHA class, heart failure physiology, and medication use. The plot shows point estimates with 95% confidence intervals, indicating relative effects and statistical significance in several subgroups.*
FDA Label Image

Figure 10 (Jardiance 08d)

Figure 10 (Jardiance 08d)
A Kaplan-Meier curve showing the estimated cumulative incidence function (%) over days since randomization for Empagliflozin 10 mg versus placebo. The graph illustrates lower cumulative incidence for Empagliflozin 10 mg compared to placebo, with hazard ratio and confidence interval data comparing the two treatments. A table below the chart displays the number of patients at risk over time for both groups.*
FDA Label Image

Figure 11 (Jardiance 08e)

Figure 11 (Jardiance 08e)
A line graph comparing the mean number of events over days since randomization between patients treated with Empagliflozin 10 mg and placebo. The y-axis represents the mean number of events, and the x-axis shows days since randomization. The graph includes patient numbers at risk for each group across time points. The data show lower event accumulation for Empagliflozin 10 mg compared to placebo.*
FDA Label Image

Figure 12 (Jardiance 08f)

Figure 12 (Jardiance 08f)
A forest plot chart showing hazard ratios comparing Empagliflozin 10 mg to placebo across various subgroups, including diabetes status, age, sex, race, BMI, kidney function (eGFR), NYHA class, LVEF, NT-proBNP levels, and baseline use of mineralocorticoid receptor antagonists (MRA). The chart displays event counts, hazard ratios with 95% confidence intervals, and visually represents which treatment was better.*
FDA Label Image

Figure 13 (Jardiance 08g)

Figure 13 (Jardiance 08g)
A line graph comparing the estimated cumulative incidence function percentages over time in months since randomization for Empagliflozin 10 mg tablets versus placebo. The graph includes patient counts at risk for each group across months and indicates hazard ratio (HR) with 95% confidence interval and P-value for the comparison.*
FDA Label Image

Figure 14 (Jardiance 08h)

Figure 14 (Jardiance 08h)
A forest plot comparing hazard ratios for Empagliflozin 10 mg versus placebo across various subgroups, including diabetes status, baseline kidney function (eGFR), albuminuria levels, age, sex, race, history of renal disease, and use of RAS inhibitors. The plot displays hazard ratios with 95% confidence intervals for each subgroup and overall, illustrating the relative risk favoring either Empagliflozin or placebo.*
FDA Label Image

Qr Code (Jardiance 08i)

FDA Label Image

10mg Bottle Label (09daa78d F417 436c A29e 029c015ca6d6 01)

10mg Bottle Label (09daa78d F417 436c A29e 029c015ca6d6 01)
Jardiance 10 mg (empagliflozin) film-coated tablets prescription drug label. The label indicates the product contains approximately 720 tablets, includes dosage storage instructions (store at 20°C to 25°C), distributor Cardinal Health 107, LLC, and manufacturer details. It includes a warning to keep out of reach of children and barcode information.*
FDA Label Image

25mg Bottle Label (09daa78d F417 436c A29e 029c015ca6d6 00)

25mg Bottle Label (09daa78d F417 436c A29e 029c015ca6d6 00)
Jardiance 25 mg film-coated tablets label displaying the generic name empagliflozin. The label notes prescription use only and includes a warning to keep out of reach of children. It indicates a quantity of approximately 990 tablets. Storage instructions and distributor information (Cardinal Health, Dublin, OH) are also present, along with barcodes and manufacturing details from Italy and the USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.